Citius Pharmaceuticals, Inc. (CTXR): Operating Income
-$38.53M
Year ended 2025-09-30
-$61.38M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | -$38.53M | n/m | 2025-12-23, From 2024-10-01 |
| 2024-09-30 | -$42.00M | n/m | 2025-12-23, From 2023-10-01 |
| 2023-09-30 | -$36.73M | n/m | 2024-12-27, From 2022-10-01 |
| 2022-09-30 | -$33.32M | n/m | 2023-12-29, From 2021-10-01 |
| 2021-09-30 | -$23.53M | n/m | 2022-12-22, From 2020-10-01 |
| 2020-09-30 | -$17.71M | n/m | 2021-12-15, From 2019-10-01 |
| 2019-09-30 | -$15.60M | n/m | 2020-12-16, From 2018-10-01 |
| 2018-09-30 | -$13.79M | n/m | 2019-12-16, From 2017-10-01 |
| 2017-09-30 | -$9.99M | n/m | 2019-12-16, From 2016-10-01 |
| 2016-09-30 | -$7.45M | n/m | 2018-12-11, From 2015-10-01 |
| 2015-09-30 | -$3.23M | n/m | 2017-12-13, From 2014-10-01 |
| 2014-09-30 | -$653.8K | n/m | 2016-12-23, From 2013-10-01 |
| 2013-09-30 | -$28.1K | n/m | 2014-02-06, From 2012-10-01 |
| 2012-09-30 | -$19.6K | n/m | 2014-02-06, From 2011-10-01 |
| 2011-09-30 | -$25.6K | n/a | 2013-01-15, From 2010-10-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | 2025-09-30 | -$38.53M | n/m |
| Silence Therapeutics plc (SLN) | 2025-12-31 | -$91.08M | n/m |
| Acrivon Therapeutics, Inc. (ACRV) | 2025-12-31 | -$84.11M | n/m |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | -$84.35M | n/m |
| Seres Therapeutics, Inc. (MCRB) | 2025-12-31 | -$93.97M | n/m |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $49.11M | +150.6% |
| Monopar Therapeutics (MNPR) | 2025-12-31 | -$16.70M | n/m |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | -$104.57M | n/m |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | -$45.90M | n/m |
Compare CTXR, SLN, ACRV, ZOMDF side by side · Screen every company in Pharmaceutical Preparations ↗